{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T15:27:55Z","timestamp":1780500475672,"version":"3.54.1"},"reference-count":47,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","pet.theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["PET Clinics"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1016\/j.cpet.2023.02.008","type":"journal-article","created":{"date-parts":[[2023,3,28]],"date-time":"2023-03-28T13:54:33Z","timestamp":1680011673000},"page":"361-367","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Fibroblast Activation Protein Inhibitor Theranostics"],"prefix":"10.1016","volume":"18","author":[{"given":"Rainer","family":"Hamacher","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helena","family":"Lanzafame","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilektra A.","family":"Mavroeidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim M.","family":"Pabst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lukas","family":"Kessler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phyllis F.","family":"Cheung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Bauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Herrmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-Ulrich","family":"Schildhaus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens T.","family":"Siveke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang P.","family":"Fendler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cpet.2023.02.008_bib1","unstructured":"Board WCoTE. Soft Tissue and Bone Tumours International Agency for Research on Cancer. 2020;3(5th Edition)."},{"issue":"2","key":"10.1016\/j.cpet.2023.02.008_bib2","doi-asserted-by":"crossref","first-page":"e0246958","DOI":"10.1371\/journal.pone.0246958","article-title":"Nationwide incidence of sarcomas and connective tissue tumors of intermediate malignancy over four years using an expert pathology review network","volume":"16","author":"de Pinieux","year":"2021","journal-title":"PLoS One"},{"issue":"11","key":"10.1016\/j.cpet.2023.02.008_bib3","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1016\/j.annonc.2021.07.006","article-title":"Soft tissue and visceral sarcomas: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up(\u2606)","volume":"32","author":"Gronchi","year":"2021","journal-title":"Ann Oncol"},{"issue":"12","key":"10.1016\/j.cpet.2023.02.008_bib4","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1016\/j.annonc.2021.08.1995","article-title":"Bone sarcomas: ESMO-EURACAN-GENTURIS-ERN PaedCan clinical practice guideline for diagnosis, treatment and follow-up","volume":"32","author":"Strauss","year":"2021","journal-title":"Ann Oncol"},{"issue":"8","key":"10.1016\/j.cpet.2023.02.008_bib5","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1016\/j.annonc.2021.04.014","article-title":"A\u00a0randomized phase III trial comparing trabectedin to best supportive care in patients with pre-treated soft tissue sarcoma: T-SAR, a French Sarcoma Group trial","volume":"32","author":"Le Cesne","year":"2021","journal-title":"Ann Oncol"},{"issue":"9829","key":"10.1016\/j.cpet.2023.02.008_bib6","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1016\/S0140-6736(12)60651-5","article-title":"Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"379","author":"van der Graaf","year":"2012","journal-title":"Lancet"},{"issue":"18","key":"10.1016\/j.cpet.2023.02.008_bib7","doi-asserted-by":"crossref","first-page":"7235","DOI":"10.1073\/pnas.87.18.7235","article-title":"Cell surface glycoprotein of reactive stromal fibroblasts as a potential antibody target in human epithelial cancers","volume":"87","author":"Garin-Chesa","year":"1990","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5\u20136","key":"10.1016\/j.cpet.2023.02.008_bib8","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1002\/prca.201300095","article-title":"Understanding fibroblast activation protein (FAP): substrates, activities, expression and targeting for cancer therapy","volume":"8","author":"Hamson","year":"2014","journal-title":"Proteonomics Clin Appl"},{"issue":"3","key":"10.1016\/j.cpet.2023.02.008_bib9","doi-asserted-by":"crossref","first-page":"e0116683","DOI":"10.1371\/journal.pone.0116683","article-title":"Fibroblast activation protein overexpression and clinical implications in solid tumors: a meta-analysis","volume":"10","author":"Liu","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.cpet.2023.02.008_bib10","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/B978-0-12-394308-8.00003-0","article-title":"Fibroblast activation protein-\u03b1: a key modulator of the microenvironment in multiple pathologies","volume":"297","author":"Kelly","year":"2012","journal-title":"Int Rev Cell Mol Biol"},{"issue":"9","key":"10.1016\/j.cpet.2023.02.008_bib11","doi-asserted-by":"crossref","first-page":"3110","DOI":"10.1073\/pnas.85.9.3110","article-title":"Cell-surface glycoproteins of human sarcomas: differential expression in normal and malignant tissues and cultured cells","volume":"85","author":"Rettig","year":"1988","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"10.1016\/j.cpet.2023.02.008_bib12","first-page":"44","article-title":"Stromal antigen targeting by a humanised monoclonal antibody: an early phase II trial of sibrotuzumab in patients with metastatic colorectal cancer","volume":"26","author":"Hofheinz","year":"2003","journal-title":"Onkologie"},{"issue":"5","key":"10.1016\/j.cpet.2023.02.008_bib13","first-page":"1639","article-title":"A\u00a0Phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer","volume":"9","author":"Scott","year":"2003","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1016\/j.cpet.2023.02.008_bib14","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1200\/JCO.1994.12.6.1193","article-title":"Antibody targeting in metastatic colon cancer: a phase I study of monoclonal antibody F19 against a cell-surface protein of reactive tumor stromal fibroblasts","volume":"12","author":"Welt","year":"1994","journal-title":"J\u00a0Clin Oncol"},{"issue":"5","key":"10.1016\/j.cpet.2023.02.008_bib15","doi-asserted-by":"crossref","first-page":"3203","DOI":"10.3892\/mmr.2015.3197","article-title":"Fibroblast activation protein \u03b1 in tumor microenvironment: recent progression and implications (review)","volume":"11","author":"Zi","year":"2015","journal-title":"Mol Med Rep"},{"issue":"2","key":"10.1016\/j.cpet.2023.02.008_bib16","doi-asserted-by":"crossref","first-page":"160","DOI":"10.2967\/jnumed.120.244806","article-title":"The latest developments in imaging of fibroblast activation protein","volume":"62","author":"Altmann","year":"2021","journal-title":"J\u00a0Nucl Med"},{"issue":"6","key":"10.1016\/j.cpet.2023.02.008_bib17","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1007\/s00259-020-05132-y","article-title":"Biodistribution, pharmacokinetics, dosimetry of [(68)Ga]Ga-DOTA.SA.FAPi, and the head-to-head comparison with [(18)F]F-FDG PET\/CT in patients with various cancers","volume":"48","author":"Ballal","year":"2021","journal-title":"Eur J Nucl Med Mol Imag"},{"issue":"3","key":"10.1016\/j.cpet.2023.02.008_bib18","doi-asserted-by":"crossref","first-page":"386","DOI":"10.2967\/jnumed.118.215913","article-title":"68)Ga-FAPI PET\/CT: biodistribution and preliminary dosimetry estimate of 2 DOTA-containing FAP-targeting agents in patients with various cancers","volume":"60","author":"Giesel","year":"2019","journal-title":"J\u00a0Nucl Med"},{"issue":"6","key":"10.1016\/j.cpet.2023.02.008_bib19","doi-asserted-by":"crossref","first-page":"801","DOI":"10.2967\/jnumed.119.227967","article-title":"68)Ga-FAPI PET\/CT: tracer uptake in 28 different kinds of cancer","volume":"60","author":"Kratochwil","year":"2019","journal-title":"J\u00a0Nucl Med"},{"issue":"9","key":"10.1016\/j.cpet.2023.02.008_bib20","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.2967\/jnumed.118.210443","article-title":"Development of quinoline-based theranostic ligands for the targeting of fibroblast activation protein","volume":"59","author":"Lindner","year":"2018","journal-title":"J\u00a0Nucl Med"},{"issue":"10","key":"10.1016\/j.cpet.2023.02.008_bib21","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.2967\/jnumed.118.224469","article-title":"Development of fibroblast activation protein-targeted radiotracers with improved tumor retention","volume":"60","author":"Loktev","year":"2019","journal-title":"J\u00a0Nucl Med"},{"issue":"9","key":"10.1016\/j.cpet.2023.02.008_bib22","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.2967\/jnumed.118.210435","article-title":"A\u00a0tumor-imaging method targeting cancer-associated fibroblasts","volume":"59","author":"Loktev","year":"2018","journal-title":"J\u00a0Nucl Med"},{"issue":"1","key":"10.1016\/j.cpet.2023.02.008_bib23","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s41181-020-00102-z","article-title":"Targeting fibroblast activation protein (FAP): next generation PET radiotracers using squaramide coupled bifunctional DOTA and DATA(5m) chelators","volume":"5","author":"Moon","year":"2020","journal-title":"EJNMMI Radiopharm Chem"},{"issue":"3","key":"10.1016\/j.cpet.2023.02.008_bib24","doi-asserted-by":"crossref","first-page":"415","DOI":"10.2967\/jnumed.120.259192","article-title":"Feasibility, biodistribution, and preliminary dosimetry in peptide-targeted radionuclide therapy of diverse adenocarcinomas using (177)Lu-FAP-2286: first-in-humans results","volume":"63","author":"Baum","year":"2022","journal-title":"J\u00a0Nucl Med"},{"issue":"8","key":"10.1016\/j.cpet.2023.02.008_bib25","doi-asserted-by":"crossref","first-page":"2889","DOI":"10.1007\/s00259-022-05700-4","article-title":"Head-to-head evaluation of [(18)F]FDG and [(68) Ga]Ga-DOTA-FAPI-04 PET\/CT in recurrent soft tissue sarcoma","volume":"49","author":"Gu","year":"2022","journal-title":"Eur J Nucl Med Mol Imag"},{"issue":"1","key":"10.1016\/j.cpet.2023.02.008_bib26","doi-asserted-by":"crossref","first-page":"89","DOI":"10.2967\/jnumed.121.262096","article-title":"68)Ga-FAPI as a diagnostic tool in sarcoma: data from the (68)Ga-FAPI PET prospective observational trial","volume":"63","author":"Kessler","year":"2022","journal-title":"J\u00a0Nucl Med"},{"issue":"12","key":"10.1016\/j.cpet.2023.02.008_bib27","doi-asserted-by":"crossref","first-page":"3918","DOI":"10.1007\/s00259-021-05374-4","article-title":"Novel FAP ligands enable improved imaging contrast in sarcoma patients due to FAPI-PET\/CT","volume":"48","author":"Koerber","year":"2021","journal-title":"Eur J Nucl Med Mol Imag"},{"issue":"2","key":"10.1016\/j.cpet.2023.02.008_bib28","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1007\/s00223-017-0372-2","article-title":"Biology of bone sarcomas and new therapeutic developments","volume":"102","author":"Brown","year":"2018","journal-title":"Calcif Tissue Int"},{"issue":"13","key":"10.1016\/j.cpet.2023.02.008_bib29","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1001\/jama.2020.1707","article-title":"Effect of doxorubicin plus olaratumab vs doxorubicin plus placebo on survival in patients with advanced soft tissue sarcomas: the ANNOUNCE randomized clinical trial","volume":"323","author":"Tap","year":"2020","journal-title":"JAMA"},{"issue":"8","key":"10.1016\/j.cpet.2023.02.008_bib30","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1038\/nrc3087","article-title":"Advances in sarcoma genomics and new therapeutic targets","volume":"11","author":"Taylor","year":"2011","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.cpet.2023.02.008_bib31","first-page":"18","article-title":"The role of mesenchymal stem\/progenitor cells in sarcoma: update and dispute","volume":"1","author":"Yang","year":"2014","journal-title":"Stem Cell Invest"},{"key":"10.1016\/j.cpet.2023.02.008_bib32","first-page":"10","article-title":"Characterization of cancer stroma markers: in silico analysis of an mRNA expression database for fibroblast activation protein and endosialin","volume":"5","author":"Dolznig","year":"2005","journal-title":"Cancer Immun"},{"issue":"4","key":"10.1016\/j.cpet.2023.02.008_bib33","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1111\/j.1365-2559.2009.03399.x","article-title":"Histogenesis-specific expression of fibroblast activation protein and dipeptidylpeptidase-IV in human bone and soft tissue tumours","volume":"55","author":"Dohi","year":"2009","journal-title":"Histopathology"},{"issue":"12","key":"10.1016\/j.cpet.2023.02.008_bib34","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","article-title":"Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer","volume":"385","author":"Sartor","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.cpet.2023.02.008_bib35","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa1607427","article-title":"Phase 3 trial of (177)Lu-dotatate for midgut neuroendocrine tumors","volume":"376","author":"Strosberg","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"11","key":"10.1016\/j.cpet.2023.02.008_bib36","doi-asserted-by":"crossref","first-page":"e523","DOI":"10.1097\/RLU.0000000000003810","article-title":"Feasibility and therapeutic potential of 177Lu-fibroblast activation protein inhibitor-46 for patients with relapsed or refractory cancers: a preliminary study","volume":"46","author":"Assadi","year":"2021","journal-title":"Clin Nucl Med"},{"issue":"12","key":"10.1016\/j.cpet.2023.02.008_bib37","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.3390\/ph14121212","article-title":"First-in-human results on the biodistribution, pharmacokinetics, and dosimetry of [(177)Lu]Lu-DOTA.SA.FAPi and [(177)Lu]Lu-DOTAGA.(SA.FAPi)(2)","volume":"14","author":"Ballal","year":"2021","journal-title":"Pharmaceuticals"},{"issue":"1","key":"10.1016\/j.cpet.2023.02.008_bib38","first-page":"65","article-title":"Novel fibroblast activation protein inhibitor-based targeted theranostics for radioiodine-refractory differentiated thyroid cancer patients: a pilot study","volume":"32","author":"Ballal","year":"2022","journal-title":"Thyroid"},{"issue":"19","key":"10.1016\/j.cpet.2023.02.008_bib39","doi-asserted-by":"crossref","first-page":"4346","DOI":"10.1158\/1078-0432.CCR-22-1432","article-title":"Safety and efficacy of 90Y-FAPI-46 radioligand therapy in patients with advanced sarcoma and other cancer entities","volume":"28","author":"Fendler","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"5","key":"10.1016\/j.cpet.2023.02.008_bib40","first-page":"727","article-title":"Initial clinical experience with (90)Y-FAPI-46 radioligand therapy for advanced-stage solid tumors: a case series of 9 patients","volume":"63","author":"Ferdinandus","year":"2022","journal-title":"J\u00a0Nucl Med"},{"issue":"9","key":"10.1016\/j.cpet.2023.02.008_bib41","doi-asserted-by":"crossref","first-page":"3011","DOI":"10.1007\/s00259-021-05273-8","article-title":"[(153)Sm]Samarium-labeled FAPI-46 radioligand therapy in a patient with lung metastases of a sarcoma","volume":"48","author":"Kratochwil","year":"2021","journal-title":"Eur J Nucl Med Mol Imag"},{"issue":"1","key":"10.1016\/j.cpet.2023.02.008_bib42","doi-asserted-by":"crossref","first-page":"422","DOI":"10.7150\/thno.68182","article-title":"Evans blue-modified radiolabeled fibroblast activation protein inhibitor as long-acting cancer therapeutics","volume":"12","author":"Wen","year":"2022","journal-title":"Theranostics"},{"issue":"11","key":"10.1016\/j.cpet.2023.02.008_bib43","doi-asserted-by":"crossref","first-page":"3651","DOI":"10.1007\/s00259-022-05842-5","article-title":"Preclinical evaluation of FAP-2286 for fibroblast activation protein targeted radionuclide imaging and therapy","volume":"49","author":"Zboralski","year":"2022","journal-title":"Eur J Nucl Med Mol Imag"},{"issue":"10","key":"10.1016\/j.cpet.2023.02.008_bib44","doi-asserted-by":"crossref","first-page":"3640","DOI":"10.1021\/acs.molpharmaceut.2c00424","article-title":"Development of fibroblast activation protein inhibitor-based dimeric radiotracers with improved tumor retention and antitumor efficacy","volume":"19","author":"Zhao","year":"2022","journal-title":"Mol Pharm"},{"issue":"11","key":"10.1016\/j.cpet.2023.02.008_bib45","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.2967\/jnumed.120.248062","article-title":"Combination strategies to improve targeted radionuclide therapy","volume":"61","author":"Chan","year":"2020","journal-title":"J\u00a0Nucl Med"},{"issue":"9","key":"10.1016\/j.cpet.2023.02.008_bib46","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/s41573-020-0073-9","article-title":"Radiopharmaceutical therapy in cancer: clinical advances and challenges","volume":"19","author":"Sgouros","year":"2020","journal-title":"Nat Rev Drug Discov"},{"issue":"3","key":"10.1016\/j.cpet.2023.02.008_bib47","doi-asserted-by":"crossref","first-page":"296","DOI":"10.2967\/jnumed.120.256271","article-title":"Fapi PET\/CT: will it end the hegemony of (18)F-fdg in oncology?","volume":"62","author":"Hicks","year":"2021","journal-title":"J\u00a0Nucl Med"}],"container-title":["PET Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556859823000214?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556859823000214?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T11:11:46Z","timestamp":1761563506000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1556859823000214"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":47,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["S1556859823000214"],"URL":"https:\/\/doi.org\/10.1016\/j.cpet.2023.02.008","relation":{},"ISSN":["1556-8598"],"issn-type":[{"value":"1556-8598","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Fibroblast Activation Protein Inhibitor Theranostics","name":"articletitle","label":"Article Title"},{"value":"PET Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cpet.2023.02.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}